CN106008720A - Fusion protein of horseradish peroxidase and antibody fragment and application - Google Patents
Fusion protein of horseradish peroxidase and antibody fragment and application Download PDFInfo
- Publication number
- CN106008720A CN106008720A CN201610356626.5A CN201610356626A CN106008720A CN 106008720 A CN106008720 A CN 106008720A CN 201610356626 A CN201610356626 A CN 201610356626A CN 106008720 A CN106008720 A CN 106008720A
- Authority
- CN
- China
- Prior art keywords
- antibody
- fusion protein
- lysozyme
- nano antibody
- horseradish peroxidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 55
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 55
- 108010001336 Horseradish Peroxidase Proteins 0.000 title claims abstract description 36
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 102000016943 Muramidase Human genes 0.000 claims description 37
- 108010014251 Muramidase Proteins 0.000 claims description 37
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 37
- 229960000274 lysozyme Drugs 0.000 claims description 37
- 235000010335 lysozyme Nutrition 0.000 claims description 37
- 239000004325 lysozyme Substances 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 230000001130 anti-lysozyme effect Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 33
- 108090000790 Enzymes Proteins 0.000 abstract description 33
- 230000004071 biological effect Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000003018 immunoassay Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 33
- 229940088598 enzyme Drugs 0.000 description 32
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 238000002372 labelling Methods 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 101100133350 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nhp-1 gene Proteins 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000002277 temperature effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000251476 Chimaera monstrosa Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OUCQRPPXFFXWIT-UHFFFAOYSA-N NC1=CC=CC=C1.NNC(NN)=O Chemical group NC1=CC=CC=C1.NNC(NN)=O OUCQRPPXFFXWIT-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention provides a fusion protein. The fusion protein is formed by connecting an anti-iysozyme antibody or a variable region fragment of the anti-iysozyme antibody with a horseradish peroxidase reporter gene protein in series, the invention further provides a preparation method and an application of the fusion protein. The fusion protein is used for immunoassay which takes an immunolabelling technique as a basis, so that good biological activities of enzymes and the antibody are kept, and the detection efficiency is higher.
Description
Technical field
The invention discloses a kind of fusion protein and immunology application thereof, belong to genetic engineering and immunity
Field.
Background technology
Antibody (Antibody, Ab) refers to class shape after antigenic substance stimulates body immune system
Become, have and corresponding antigens material occur specific binding reaction immunoglobulin.Antibody is
The important products of immunne response, is primarily present in blood, tissue fluid and exocrine secretion, therefore will
Antibody-mediated immunity is referred to as humoral immunization.Antibody molecule is produced by bone-marrow-derived lymphocyte, and it is by two
Identical heavy chain and two identical and mammal camber conservative light chain group
Become.The molecular wt of IgG is about 160kDa, and it is a complicated molecule, H chain and L chain
Launch to be formed respectively 4 and 2 domains.Two light chains of immunoglobulin and two heavy chains by
Disulfide bond connects one four peptide chain molecule of formation, constitutes the monomer of immunoglobulin molecules.Immunity ball
In protein monomer, the amino of four peptide chain two end dissociatives or the direction of carboxyl are consistent, are called
Aminoterminal (N end) and c-terminus (C end).At the N end of Ig monomer molecule, the 1/2 of light chain with
1/4 sequence of amino acid of heavy chain changes with antibody specificity difference, therefore this region is called can
Become district (Variable region, V district).This V district gives the antibody specificity with conjugated antigen.?
3/4 part of the C end of Ig polypeptide chain, remaining of light chain 1/2 and heavy chain, aminoacid quantity, kind,
Put in order and sugar content is the most more stable, therefore referred to as constant region (Constant Region, C district).
Constant region can be used as the skeleton of Ig, also has other important biologic activity many.At V
On some ad-hoc location of district, the composition of its amino acid residue and putting in order than other positions in variable region
The amino acid residue put is more volatile, therefore these positions are called hypervariable region (Hypervariable
Region, HV district), such as the 26th～32,48～55,90～95 3 position of light chain, heavy chain
The the 31st～37,51～68,84～91,101～110 four positions amino acid residue change spy
The most violent.Position, hypervariable region on light chain, heavy chain is roughly the same.In variable region, other changes are less
Part be referred to as backbone amino acid residue (Framework Residues, FR district).Ig is anti-with special
The position that former determinant combines, just in hypervariable region, is complementary determining region district so present also known as hypervariable region
(Complementary Reterminant Region, CDR).The hypervariable region of antibody, antibody anti-
The idiotypic determinant of former binding site and antibody is present in identical Ig structure, i.e. antibody molecule
The stereochemical structure of variable region spherical tips depression.
Polyclonal antibody (Polyclonal Antibody, PcAb) is to be produced by polyclone B cell group
Mixed antibody that give birth to, for multiple antigenic determinant.Because native antigen is to be divided by multiple antigen
Molecular, every kind of antigen molecule contains again many antigenic determinants, and each antigenic determinant can
Activate corresponding B cell clone, so differentiation, ripe and synthesize corresponding antibody.Monoclonal anti
Body (monoclonal antibody, McAb) refers to be activated by a B cell, breed, broken up
The daughter cell clones secrete produced, for the antibody of an antigenic determinant, i.e. by single B
The homogeneous antibody of cell clone synthesis.A kind of Ig sequence of amino acid complete phase of monoclonal antibody
With, the affinity that its antigenic specificity combines with corresponding antigens is the most identical.
Within 1975, Koehler and Milstein uses cell-fusion techniques by mouse immune splenocyte with little
Rat bone marrow tumour cell merges, and forms hybridoma.This hybridoma had both saved myeloma
The characteristic of cell Immortalization, has again immunized B cells synthesis and the ability of secreting specificity antibody.
Then the technology such as limiting dilution assay are used can to pick out energy stably excreting antibody from hybridoma
Individual cells, promotes that its propagation becomes a cell clone, secrets out of the Dan Ke of homogeneity further
Grand antibody.The hope that the foundation of hybridoma technology makes people produce a large amount of homogeneous monoclonal antibody becomes
Reality.Owing to monoclonal antibody has purity height, high specificity, titer height, can give birth in a large number
Many advantages such as product, have been widely used as diagnostic detection reagent, improve conventional immunological detection skill
Art sensitivity, specificity, accuracy and detection speed in medical diagnosis on disease and analysis and research.Exempt from
Epidemiology detection method is exactly a series of mensuration antigens of applied immunology Design Theory, antibody, immunity
The experimental technique of the cytokine of cell and secretion thereof.Interpenetrate along with interdisciplinary, immunology
The scope related to constantly expands, and new immunological detection method emerges in an endless stream.Answering of immunological method
By scope also at expanding day, not only become the important method of various clinical medical diagnosis on disease, be also many
Multi-disciplinary research provides conveniently.For improving antigen and the sensitivity of antibody test, by known anti-
The material of easily display on body or antigenic mark, by detection label, reflects anti-with or without antigen-antibody
Should, thus indirectly measure antigen or the antibody of trace.Conventional label has enzyme, fluorescein, puts
Injectivity isotope, gold colloidal and electron dense substances etc., this antigen or antibody labeling show thing
The specific reaction carried out is referred to as immunolabelling technique (Immunolabelling Technique).Exempt from
Epidemic disease labelling not only substantially increases testability, if combining with light microscopic or electron microscopy, and can be right
Tissue or intracellular test substance are accurately positioned, thus based on clinic study and examining
Disconnected offer is convenient.Immunolabelling technique is roughly divided into two big classes: a class belongs to immunohistochemistry skill
Art, the location of antigen in tissue slice or other specimen.Another kind of referred to as immunoassay
(Immunoassay), antigen or the mensuration of antibody, such as immunoenzyme technics in liquid sample
(Immunoenzymatic Technique).The immunoenzyme technics applied the earliest is immunoenzyme systematism
Learn dyeing, i.e. occur specific binding with the antibody of labelling with the antigen in specimen, when adding enzyme
During substrate, under the effect of enzyme, produce coloring matter through a series of biochemical reactions, make by light microscopic
Location determination.At present, most widely used is elisa (Enzyme Linked
Immunosorbent Assay, ELISA).This method high specificity, sensitivity is high, both can detect anti-
Body, can measure again soluble antigen.ELISA frequently with enzyme be horseradish peroxidase
(Hosradish Peroxidase, HRP) or alkali phosphatase (Alkaline Phosphatase),
Its substrate is diaminourea aniline (DAB) and 4-NPP salt (PNPP), the end respectively
Thing is decomposed, and develops the color, and can estimate or by microplate reader colorimetric.
Horseradish Peroxidase Conjugates, is by suitable with specific antibody warp for horseradish peroxidase
When method is formed by connecting.The quality of enzymic-labelled antibody depends primarily on the purity of enzyme, activity and antibody
Affinity, it is secondary good preparation method.At present, high-quality horseradish peroxidase,
Domestic existing supply of commodities, is enzyme molecule isolated and purified from plant Radix Cochleariae officinalis.Horseradish peroxidase
Enzyme uses Over-voltage protection with antibody linked.Periodic acid method is first with NaIO4Enzyme is divided
The glycan molecule of sub-surface is oxidized to aldehyde radical, combines with the amino on Ig the most again, obtained enzyme labelling
The productivity of antibody is up to 70%, and the antibody of 99% is combined with enzyme, is current most common method.?
Needing in labeling process to use chemical reagent, can affect the biologic activity of enzyme and antibody, labelling is imitated
Rate can not reach 100%, and wastes time and energy, and finally also needs to be purified enzyme labelled antibody
Except unnecessary chemical reagent and unlabelled antibody and enzyme molecule, it is reacted to take pure from labelling
The enzyme labelled antibody changed needs the time at least 1 week.
Owing to conventional antibody molecule amount is big, reach 160kD, and light by 2 heavy chains and 2
Chain is constituted, and after merging marker enzyme, molecular weight more than 200kD to be reached, the expression of antagonist can be produced
Raw adverse influence, stability also can be deteriorated.Single-chain antibody is the one of genetic engineering antibody, is
Heavy chain and the variable region of light chain of antibody by the one that flexible polypeptide is together in series, are had antigen and combine
The antibody fragment of activity.Being made up of single peptide chain, molecular weight is little, only about 30kD, Ke Yiyong
In warm labelling horseradish peroxidase.ScFv fragment and complete antibody owing to obtaining have identical
Antigenic binding property, therefore, it can utilize the method labelling ScFv, exempted from by competitiveness enzyme-linked
Epidemic disease adsorption experiment, the concentration change of therapeutic antibodies in test experience animal or human serum, carry out medicine
For dynamic experiment.It addition, except traditional H in the serum of dromedary camel2L2Outside type IgG, also
There is a kind of natural antibody lacking light chain.This H2Type antibody homodimer is referred to as only heavy chain
Antibody (HCAbs).The heavy chain of HCAbs can form three domains: N-end territory sequence
Variable region (VHH), hinge territory and two constant regions.With conventional antibodies in the heavy chain of H2 type antibody
The part that first constant region (VH1) of heavy chain is of equal value has lacked, referred to as single domain antibody.Go
Except the variable region sequences behind constant region, molecular weight only has 15kD, the diameter of about 10 nanometers, quilt
It is referred to as nano antibody (Nbs).The similar functional antibodies lacking light chain is equally with the shape of mixture
State is present in nonmammalian such as shark and ratfish.With conventional antibodies fragment, such as Fab, ScFv
Etc. comparing, Nbs is little because of its relative molecular mass, and has the character of some uniquenesses, such as immunogen
The property characteristic such as low, solubility good, stability is strong, penetrance is strong, easy expression.
There is labeling effciency based on prior art in labelling technique low, the biology of enzyme and antibody lives
Property because the impact of chemical reagent target the technical problem that declined, therefore, invention one can be protected
The immunolabelling technique of the biologic activity holding enzyme and antibody has become the reality of the art to be needed
Ask, to realize the most quickly immune detection.
It is an object of the invention to provide the biologic activity of a kind of enzyme and antibody not by chemical labeling
Impact, can realize again the most immune labeled and detection function fusion protein and methods for using them.
Summary of the invention
Based on foregoing invention purpose, inventor is intended to use the mode of DNA recombinant expression, expresses anti-
Body and the recombination fusion protein of marker enzyme, from culture medium supernatant or the broken engineering of engineering cell
Direct purification antibody and the fusion protein of marker enzyme in Cytoplasm, it is thus achieved that enzyme labelled antibody, be used for being correlated with
Immunology detection, specifically, it is simply that utilize the nano antibody of anti-hen egg-white lysozyme, preparation
The nano antibody marker enzyme fusion protein of detection hen egg-white lysozyme concentration, and it is applied to reality
Immune detection in.
Therefore, present invention firstly provides a kind of fusion protein, described fusion protein is by anti-lysozyme
Antibody or its variable region fragment are in series with horseradish peroxidase.Fusion egg of the present invention
It is by the gene of encoding antibody or antibody variable region fragment and coding Radix Cochleariae officinalis in vain on DNA level
After the reporter gene fusion of peroxidase, by recombinant expressed method, as escherichia coli,
The recombination fusion protein expressed in yeast, insect cell or mammalian cell.
Antibody or antibody fragment and the amalgamation mode of reporter gene protein, can be at antibody fragment
Aminoterminal or c-terminus merge one or several reporter gene protein, it is also possible at antibody fragment
Aminoterminal or c-terminus merge one or several reporter gene protein respectively, or at report base
Because the aminoterminal of albumen or c-terminus merge the gene of one or several antibody fragments respectively.?
Two ends are merged in the fusion protein of reporter gene protein or antibody fragment respectively, described fusion protein
In reporter gene protein and antibody fragment can be different reporter gene protein or different antibody
Fragment, is respectively directed to the different antigenic determinants of same antigen or different antigen molecules.
In a preferred embodiment, the aminoacid sequence of described nano antibody variable region is such as
Shown in SEQ ID NO:1.
In another preferred embodiment, the aminoacid sequence of described horseradish peroxidase is such as
Shown in SEQ ID NO:3.
Intervening sequence can be added between antibody fragment and horseradish peroxidase so that antibody fragment and
Reporter gene can each express and be formed the steric configuration of self, does not cause antibody fragment and report
Gene protein sterically hindered, all has corresponding biologic activity, and intervening sequence can be
(GGGGS)nFlexible polypeptide or other intervening sequence.
In a preferred embodiment, the variable region of described nano antibody and reporter gene protein
By connection peptides (GGGGS)nConnect, the wherein any integer in the 1-6 of n position
Preferably, the variable region of described nano antibody may be located at the aminoterminal of fusion protein, described
Reporter gene protein is positioned at the c-terminus of fusion protein, n=3.
Preferably, the variable region of described nano antibody can also be positioned at the c-terminus of fusion protein, institute
State reporter gene protein and be positioned at the aminoterminal of fusion protein, n=3.
Currently preferred sequence is (GGGGS)3As antibody fragment and reporter gene protein
Intervening sequence.For the ease of purified fusion protein, can increase many in the optional position of fusion protein
Polyhistidyl tags, the recombination fusion protein after expression can use the side of nickel post metal chelate chromatography
Method is purified.
Second, present invention also offers a kind of nucleotide sequence encoding above-mentioned fusion protein, described
Nucleotide sequence is as shown in SEQ ID NO:5 or 6.
3rd, the invention provides a kind of carrier containing above-mentioned nucleotide sequence, described carrier is
pCDNA3.1。
4th, present invention also offers a kind of cell containing above-mentioned carrier, described cell is 293T
Cell.
5th, the invention provides a kind of method preparing above-mentioned fusion protein, described method includes:
(1) variable region and the Radix Cochleariae officinalis of the nano antibody of the anti-lysozyme of pCDNA3.1 construction expression are used
The fusion expression vector of peroxidase, the core of the nano antibody variable region of wherein said anti-lysozyme
Thuja acid coded sequence is SEQ ID NO:2, the nucleotide coding sequence of described horseradish peroxidase
For SEQ ID NO:4；
(2) vector that step (1) obtains is entered host cell 293T；
(3) described fusion protein is gathered in the crops.
Finally, the invention provides above-mentioned fusion protein at the targeted lysozyme antigen of antibody fragment
Vitro detection in application, as Enzyme-linked Immunosorbent Assay reaction (EIA), enzyme linked immunological double antibody folder
Heart method (ELISA), SABC and immunofluorescence experiment or Western detection, and antibody
The dynamic (dynamical) test experience of drug metabolism in vivo.
In traditional immunolabelling technique, horseradish peroxidase-labeled is residual at the lysine of albumen
Base location.In the antigen binding domain of nano antibody, lysine is generally present in CDR region, is antigen
Calmodulin binding domain CaM, therefore after labelling horseradish peroxidase, nano antibody and antigen may have been blocked
Combination, cause developing the color, the most traditional labelling technique be difficult to apply to nano antibody this
On novel antibodies.And the fusion protein that the present invention provides overcomes this technological deficiency, specific sequence
Row combination ensure that in fusion protein, nano antibody and horseradish peroxidase each defining space structure
Type so that it is each there is corresponding biologic activity.The fusion protein of the present invention has lysozyme and receives
Rice antibody recognition and the ability of conjugated antigen, and the horseradish peroxidase merged can act on it
Substrate DAB develops the color, and the lysozyme nano antibody horseradish peroxidase fusion protein therefore obtained can
Using as the enzyme labelled antibody for lysozyme, for the immune detection of lysozyme concentration；Can also make
For the competitive antibody of lysozyme nano antibody, for internal pharmacokinetic studies.The present invention will
Lysozyme nano antibody HRP fusion protein is the research of pharmacokinetics in nano antibody body,
The standard curve of the nano antibody serum-concentration detection set up shows, in the concentration of 0.1-10ug/ml
In the range of, the concentration of absorbance and nano antibody is good dependency.Meanwhile, competitiveness enzyme-linked
The detection display of immunoadsorption method, after injection lysozyme nano antibody, lysozyme in rat blood serum
The concentration of nano antibody is the concentration rapid decrease in serum after 30 minutes, substantially completely generation after 3 hours
Thank.Demonstrate owing to the molecular weight of nano antibody is relatively low, there is shorter serum half-life shorter,
This result meets the technique effect expection of nano antibody, the most fully demonstrates fusion protein of the present invention
Prospect in actual applications.
Accompanying drawing explanation
Fig. 1. the structural representation of fusion protein of the present invention；
The enzyme action of Fig. 2 .pCDNA-NHP1 and pCDNA-NHP2 identifies collection of illustrative plates；
The SDS-PAGE spectrum of Fig. 3 .NHP-1 and NHP-2 fusion protein；
Fig. 4. lysozyme nano antibody horseradish peroxidase fusion protein enzyme linked immunosorbent detection result
Figure；
Fig. 5. rat blood serum lysozyme nano antibody Concentration Testing canonical plotting；
Fig. 6. the pharmacokinetic of lysozyme nano antibody in rat blood serum.
Detailed description of the invention
Further describing the present invention, advantages of the present invention and feature below in conjunction with specific embodiment will
Can be apparent along with description.But these embodiments are only exemplary, not to the present invention's
Protection domain constitutes any restriction.
Embodiment 1: preparation embodiment
1. according to aminoacid sequence and the SEQ ID of the lysozyme nano antibody of SEQ ID NO:1
The aminoacid sequence of NO:3 horseradish peroxidase, optimizes to obtain and expresses in mammalian cell
Lysozyme and horseradish peroxidase cDNA sequence SEQ ID NO:2 and SEQ ID NO:4.
2. in lysozyme nano antibody and horseradish peroxidase sequence, add flexible peptide linker
(GGGGS)3, the DNA sequence SEQ ID NO of acquisition expression NHP-1 and NHP-2 respectively:
5 and SEQ ID NO:6.Two kinds of DNA sequence of synthetic.Fig. 1 shows described fusion egg
Three kinds of white connected modes, the aminoacid at described fusion protein can also have signal peptide, be beneficial to
The secreting, expressing of fusion protein.
The most respectively NHP-1 and NHP-2 gene is cloned into carrier for expression of eukaryon pCDNA3.1's
In EcoRI and HindIII restriction enzyme site, it is thus achieved that expression vector pCDNA-NHP1 and
PCDNA-NHP2 (Fig. 2).In Fig. 2, the pCDNA-NHP1 of the most non-enzyme action；2.AflII/AvrII
PCDNA-NHP1 after double digestion；The pCDNA-NHP2 of the most non-enzyme action；4.AflII/AvrII is double
PCDNA-NHP2 after enzyme action.
The transfection of 4.293T cell: cultivated the 293T cell of 48 hours, discarded in culture dish
Culture medium, wash twice by the PBS solution of 1ml.
5. with Tip head add 1ml Trypsin liquid, digest 1 minute (37 DEG C, 5%CO2)。
Culture bottle wall is patted, it was observed that till cell splits away off completely from wall with hands.Add 1ml's
Reaction is terminated containing blood serum medium.With Tip head repeatedly pressure-vaccum, cell is made to be completely dispersed.
6. loading in centrifuge tube by culture fluid, 1000rpm is centrifuged 5min.Resuspended carefully with culture fluid
Born of the same parents, select 0.8 × 10 after cell counting6Individual cell adds a 35mm culture dish.By suitable body
Long-pending complete culture solution adds in centrifuge tube, adds gently in culture dish so that it is uniformly after mixing cell
Distribution.Culture dish is proceeded to CO2Incubator is cultivated, transfection in second day.
7. the preparation of transfection reagent: 400ul goes nuclease water add in pipe, shakes 10 seconds
Clock, dissolves smectic thing.After concussion, reagent is placed on-20 DEG C of preservations, before using, also needs concussion.Choosing
Select proper mixture ratio example (1:1-1:2/ liposome volume: DNA mass) and carry out transfectional cell.
The serum-free medium of suitable volumes is added in a transfection pipe.Add the DNA of appropriate mass,
Adding the transfection reagent of suitable volumes after concussion, again shaking.Mixed liquor is placed in room temperature
10 15 minutes.
8. suck the culture medium in culture plate, clean once with PBS or serum-free medium.
Add mixed liquor, cell is put back in incubator and cultivate one hour.After then, remove mixed liquor,
Add afterwards and continue to cultivate 48-72 hour entirely without blood serum medium.
9. the SDS-PAGE electrophoresis detection of nano antibody horseradish peroxidase fusion protein: take
The 293T cell culture medium supernatant that 10 microlitres transfect after cultivating 3 days, adds 10 microlitres reduction respectively and (contains
Beta mercaptoethanol) and the sample-loading buffer of non-reduced electrophoresis (without beta mercaptoethanol), boil
Boil 5 minutes, after ice bath cooling, the SDS-polyacrylamide gel of upper 15%, 120V electrophoresis 30-40
Minute to bromophenol blue arrive glue bottom, take off gel, stained over night in Coomassie Brillant Blue solution,
The expression of recombiant protein is observed after decolouring.(seeing Fig. 3).
The SDS-PAGE electrophoresis detection of nano antibody horseradish peroxidase fusion protein: take 10 micro-
Rise the 293T cell culture medium supernatant of transfection after cultivating 3 days, add 10 microlitres respectively and reduce (containing beta
Mercaptoethanol) and the sample-loading buffer of non-reduced electrophoresis (without beta mercaptoethanol), boil 5
Minute, after ice bath cooling, the SDS-polyacrylamide gel of upper 15%, 120V electrophoresis 30-40
Minute to bromophenol blue arrive glue bottom, take off gel, stained over night in Coomassie Brillant Blue solution,
The expression (seeing Fig. 3) of recombiant protein is observed after decolouring.In Fig. 3,1.293T cell conditioned medium
(reduction)；2.293T cell conditioned medium (non-reduced)；3.NHP-1 transfects 293T cell conditioned medium
(reduction)；4.NHP-1 transfectional cell supernatant (non-reduced)；5.NHP-2 transfectional cell supernatant is (also
Former)；6.NHP-2 transfectional cell supernatant (non-reduced).Tie from the SDS-PAGE electrophoresis of Fig. 3
Fruit is it can be seen that NHP-1 and NHP-2 fusion protein has in the culture medium supernatant of 293T cell
Significantly secreting, expressing, purity is the highest, and the most non-reducing albumen mobility relatively reduces albumen
Mobility is higher, illustrates that in fusion protein, nano antibody and horseradish peroxidase each defining sky
Between configuration, it should there is corresponding biologic activity.
The detection of embodiment 2. fusion protein immunization activity
Take hen egg-white lysozyme, be configured to the solution of 10ug/ml with PBS, take 96 hole ELISA Plate,
Every hole 100 microlitre is coated overnight.Within second day, rinse each hole with PBST, with the BSA solution of 0.5%
Close 1 hour, take the 293T cell culture medium supernatant after 100 microlitre transfections, add in hand-hole, room
Temperature lucifuge is placed 1 hour, and PBST rinses 3 times, adds 100 microlitre DAB chromogenic substrates, room temperature
Lucifuge is reacted 15 minutes, visual observations colour developing situation (seeing Fig. 4).In Fig. 4,1. blank
NHP-1 transfects 293T cell conditioned medium；2. lysozyme be coated 4 × NHP-1 transfection 293T is thin in dilution
Born of the same parents' supernatant；3. lysozyme is coated 10 × dilution NHP-1 and transfects 293T cell conditioned medium；4. lysozyme bag
293T cell conditioned medium is transfected by 4 × dilution NHP-2；5. lysozyme is coated 10 × dilution NHP-2
Rotaring redyeing 293 cell supernatant；6. blank NHP-2 transfects 293T cell conditioned medium.
Figure 4, it is seen that in the hole being coated lysozyme, have horseradish peroxidase
Specific color, and in control wells, not colour developing, it was demonstrated that fusion protein has lysozyme nanometer and resists
Body identification and the ability of conjugated antigen, and the horseradish peroxidase merged can act on its substrate
DAB develops the color, and the lysozyme nano antibody horseradish peroxidase fusion protein therefore obtained can be made
For the enzyme labelled antibody for lysozyme, for the immune detection of lysozyme concentration.Can also be as molten
The competitive antibody of bacterium enzyme nano antibody, for internal pharmacokinetic studies.
The horseradish peroxidase chemical labeling of embodiment 3. nano antibody
5mg horseradish peroxidase is dissolved in 0.5ml 0.1mol/L NaHCO3In solution；Add
0.5ml 10mmol/L NaIO4Solution, mixing, cover tightly bottle stopper, room temperature lucifuge effect 2 hours.Add
0.75ml 0.1mol/L Na2CO3Mixing, is subsequently adding the anti-lysozyme nano antibody of 0.75ml purification
(15mg/ml), mixing.Weigh Sephadex G25 dry powder 0.3g, add an end opening pad glass
In cotton 5ml syringe urceolus；Subsequently above-mentioned cross-linking agent is moved into syringe jacket；Cover tightly, room
Temperature effect (lucifuge) 3 hours or 4 DEG C is overnight.With a little PBS, cross-linking agent is all washed out, collect
Eluate, adds 1/20 volume freshly prepared 5mg/ml NaBH4 solution, mixing, room temperature effect
30 minutes；Add 3/20NaBH4Solution, mixing, room temperature effect 1 hour (or 4 DEG C overnight).Will
Cross-linking agent proceeds in the super filter tube that 30kD molecular weight retains, and 4 DEG C 3000 leaves the heart 30 minutes, add
Equal-volume PBS, continues centrifugal 3 times, removes labelled reagent and unlabelled nano antibody, it is thus achieved that
The lysozyme nano antibody of horseradish peroxidase-labeled.
The enzyme-linked immunosorbent assay of the lysozyme nano antibody of horseradish peroxidase chemical labeling:
Method as described in step 10, becomes the solution of 10ug/ml, often with PBS preparation hen egg-white lysozyme
Hole 100 microlitre is coated and takes 96 hole ELISA Plate overnight.After washing is closed, each hole adds 1:10 respectively, and 1:
HRP marking nano antibody 100 microlitre after purification of 100 and 1:1000 dilutions, room temperature lucifuge
Placing 1 hour, PBST rinses 3 times, adds 100 microlitre DAB chromogenic substrates, and room temperature lucifuge is anti-
Answer 15 minutes, visual observations colour developing situation.
Each hole is showed no significantly colour developing.Owing to HRP is the lysine residue position being marked at albumen
Putting, in the antigen binding domain of nano antibody, lysine is generally present in CDR region, is the knot of antigen
Close region, therefore after labelling HRP, the combination of nano antibody and antigen may have been blocked, the most not
Can colour developing.
In embodiment 4. lysozyme nano antibody HRP fusion protein medicine generation in nano antibody body, is dynamic
The research of mechanics
Take rat blood serum, be separately added into 0.1, the bacteriolyze of 0.5,2,10,50 and 200ug/ml concentration
Enzyme nano antibody.Take hen egg-white lysozyme, be configured to the solution of 10ug/ml with PBS, take 96 holes
ELISA Plate, every hole 100 microlitre is coated overnight.Within second day, rinse each hole with PBST, with 0.5%
BSA solution is closed 1 hour, after being blended with the rat blood serum dilution 50 times of lysozyme nano antibody,
Taking 50 microlitres respectively and join in 96 orifice plates, each concentration repeats 3 holes, in each hole,
Add 50 microlitres and contain 10ug/ml lysozyme nano antibody horseradish peroxidase fusion protein
PBS, incubated at room 2 hours.After PBST washs 96 orifice plate 3 times, add DAB and show
Color, after 0.2M sulphuric acid terminates reaction, reads absorbance under 450nm wavelength condition, and foundation is received
The standard curve (seeing Fig. 5) of rice antibody sera concentration detection, from figure 5 it can be seen that
In the concentration range of 0.1-10ug/ml, the concentration of absorbance and nano antibody is good dependency.
Take the Wistar rat of body weight about 200 grams, according to the dosage of 10mg/kg body weight, pass through
The method of tail vein injection, injects lysozyme nano antibody to rat.Blood is taken once every 30 minutes,
Take 8 times altogether.According to lysozyme in aforesaid competitiveness enzyme-linked immunoadsorption method detection rat blood serum
The concentration of nano antibody.Owing to the molecular weight of nano antibody is relatively low, can be fallen by renal excretion,
Therefore its serum half-life is shorter, the concentration rapid decrease in serum, base after 3 hours after 30 minutes
(seeing Fig. 6) is fallen in this metabolism completely.
Claims (11)
1. a fusion protein, it is characterised in that described fusion protein by anti-lysozyme antibody or its
Variable region fragment is in series with horseradish peroxidase reporter gene protein.
Albumen the most according to claim 1, it is characterised in that described antibody is nano antibody,
The aminoacid sequence of its variable region fragment is as shown in SEQ ID NO:1.
Albumen the most according to claim 2, it is characterised in that described horseradish peroxidase
The aminoacid sequence of reporter gene protein is as shown in SEQ ID NO:3.
Albumen the most according to claim 3, it is characterised in that described nano antibody variable
District and reporter gene protein are by connection peptides (GGGGS)nConnect, arbitrary whole during wherein n is 1-6
Number.
Albumen the most according to claim 4, it is characterised in that described nano antibody variable
District is positioned at the aminoterminal of fusion protein, and described reporter gene protein is positioned at the c-terminus of fusion protein,
N=3.
Albumen the most according to claim 4, it is characterised in that described nano antibody variable
District is positioned at the c-terminus of fusion protein, and described reporter gene protein is positioned at the aminoterminal of fusion protein,
N=3.
7. the nucleotide sequence encoding albumen described in claim 5 or 6, it is characterised in that
Described nucleotide sequence is as shown in SEQ ID NO:5 or 6.
8. the carrier containing nucleotide sequence described in claim 7, it is characterised in that described
Carrier is pCDNA3.1.
9. the cell containing carrier described in claim 8, it is characterised in that described cell is
293T cell.
10. the method preparing the arbitrary described fusion protein of claim 1-5, described method includes:
(1) variable region and the Radix Cochleariae officinalis of the nano antibody of the anti-lysozyme of pCDNA3.1 construction expression are used
The fusion expression vector of peroxidase, the variable region of the nano antibody of wherein said anti-lysozyme
Nucleotide coding sequence is SEQ ID NO:2, the nucleotide coding sequence of described horseradish peroxidase
It is classified as SEQ ID NO:4；
(2) vector that step (1) obtains is entered host cell 293T；
(3) described fusion protein is gathered in the crops.
The 11. arbitrary described fusion protein of claim 1-6 are in the immunologic detection method of lysozyme
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610356626.5A CN106008720A (en) | 2016-05-25 | 2016-05-25 | Fusion protein of horseradish peroxidase and antibody fragment and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610356626.5A CN106008720A (en) | 2016-05-25 | 2016-05-25 | Fusion protein of horseradish peroxidase and antibody fragment and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106008720A true CN106008720A (en) | 2016-10-12 |
Family
ID=57094788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610356626.5A Pending CN106008720A (en) | 2016-05-25 | 2016-05-25 | Fusion protein of horseradish peroxidase and antibody fragment and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106008720A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108484779A (en) * | 2018-04-14 | 2018-09-04 | 深圳市国创纳米抗体技术有限公司 | A kind of fusion protein and the application of nano antibody and human placental alkaline phosphatase |
| CN109781972A (en) * | 2019-01-16 | 2019-05-21 | 深圳大学 | A kind of immunoquantitative detection method and application |
| CN110257339A (en) * | 2019-06-21 | 2019-09-20 | 西北农林科技大学 | Cell line expressing anti-Newcastle disease virus fusion protein and its construction method and application |
| CN112481279A (en) * | 2020-11-07 | 2021-03-12 | 武汉爱博泰克生物科技有限公司 | Application of horseradish peroxidase gene as reporter gene |
| CN116874612A (en) * | 2023-09-05 | 2023-10-13 | 南京拂晓生物科技有限公司 | A Ki-67 biofusion enzyme antibody with signaling protein tag and its application |
| CN117694469A (en) * | 2024-02-02 | 2024-03-15 | 潍坊新希望六和饲料科技有限公司 | Feed additive for improving quality of eggshells of brown-shell eggs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) * | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| CN1942203A (en) * | 2004-06-04 | 2007-04-04 | 金克克国际有限公司 | Screening method using antibody heavy chains |
-
2016
- 2016-05-25 CN CN201610356626.5A patent/CN106008720A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) * | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| CN1942203A (en) * | 2004-06-04 | 2007-04-04 | 金克克国际有限公司 | Screening method using antibody heavy chains |
Non-Patent Citations (11)
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108484779A (en) * | 2018-04-14 | 2018-09-04 | 深圳市国创纳米抗体技术有限公司 | A kind of fusion protein and the application of nano antibody and human placental alkaline phosphatase |
| CN109781972A (en) * | 2019-01-16 | 2019-05-21 | 深圳大学 | A kind of immunoquantitative detection method and application |
| CN110257339A (en) * | 2019-06-21 | 2019-09-20 | 西北农林科技大学 | Cell line expressing anti-Newcastle disease virus fusion protein and its construction method and application |
| CN112481279A (en) * | 2020-11-07 | 2021-03-12 | 武汉爱博泰克生物科技有限公司 | Application of horseradish peroxidase gene as reporter gene |
| CN116874612A (en) * | 2023-09-05 | 2023-10-13 | 南京拂晓生物科技有限公司 | A Ki-67 biofusion enzyme antibody with signaling protein tag and its application |
| CN116874612B (en) * | 2023-09-05 | 2024-02-20 | 南京拂晓生物科技有限公司 | A Ki-67 biofusion enzyme antibody with signaling protein tag and its application |
| CN117694469A (en) * | 2024-02-02 | 2024-03-15 | 潍坊新希望六和饲料科技有限公司 | Feed additive for improving quality of eggshells of brown-shell eggs |
| CN117694469B (en) * | 2024-02-02 | 2024-04-23 | 潍坊新希望六和饲料科技有限公司 | Feed additive for improving quality of eggshells of brown-shell eggs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106008720A (en) | Fusion protein of horseradish peroxidase and antibody fragment and application | |
| CN120513255A (en) | Antibodies to dengue virus nonstructural protein 1 and related uses thereof | |
| CN108997499A (en) | A kind of anti human PD-L 1 antibody and its application | |
| CN110028582A (en) | Anti-human d-dimer antibody and its application | |
| CN112730854A (en) | Ovulation detection test strip and detection method | |
| WO2024067151A1 (en) | Anti-respiratory syncytial virus antibody and related use thereof | |
| CN106699884B (en) | Anti-human C-reactive protein antibody and application thereof | |
| CN115286715B (en) | anti-CD3 nano antibody or antigen binding portion thereof and preparation method thereof | |
| CN110407937A (en) | A kind of preparation and its application of anti-AMH monoclonal antibody | |
| CN119192368B (en) | Monoclonal antibody or antigen-binding fragment thereof for detecting folic acid and its binding protein complex, preparation method and application thereof | |
| CN118406145B (en) | Anti-phosphorylation ASC_Tyr144 antibody and application thereof | |
| CN109608542A (en) | Anti-human NGAL antibody and its application in Test paper card | |
| CN109535255A (en) | A kind of anti-human CD26 antibody and its application in detection kit | |
| CN118344485B (en) | Anti-folic acid and monoclonal antibody of binding protein complex thereof or antigen binding fragment thereof, preparation method and application thereof | |
| CN110078823A (en) | Anti-human D-Dimer antibody and its application | |
| CN108997500A (en) | A kind of anti human PD-L 1 antibody and its application | |
| CN108623684B (en) | A kind of monoclonal antibody and its application identifying Avastin | |
| CN109705221B (en) | C peptide immunogen, monoclonal antibody pair thereof and application of antibody pair in C peptide magnetic particle chemiluminescence immunoassay reagent | |
| CN118206648A (en) | Non-carboxylated matrix Gla protein antibody and application thereof | |
| CN114213541B (en) | Monoclonal antibody of totipotent nuclease and preparation method thereof | |
| CN109553682A (en) | Anti-human neutrophil gelatinase-associated lipocalin antibody and its application in Test paper card | |
| US7517663B2 (en) | Rabbit monoclonal antibody against Id1 protein | |
| CN119431573B (en) | ATG16L1 monoclonal antibody and its use | |
| CN105949311B (en) | Anti-human Procalcitonin antibody and its application | |
| CN109354626A (en) | Anti- MyoD1 protein monoclonal antibody, cell line and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |